R apid reperfusion is essential to improve survival after the onset of myocardial injury in patients with ST-segmentelevation myocardial infarction (STEMI). However, restoration of blood flow triggers reperfusion injury, which in turn increases infarct size. 1 Induction of mild hypothermia (<35°C) before reperfusion has been shown to reduce infarct size in animal models of STEMI, 2,3 as well as in small randomized trials and subgroup analyses of larger randomized trials in humans. [4] [5] [6] [7] [8] [9] As smaller infarct size is strongly correlated with greater ejection fraction and improved survival, systemic hypothermia may have long-term benefits in patients with STEMI. 10, 11 Multiple methods to establish hypothermia have been explored. Hypothermia via external surface cooling or infusion of chilled intravenous fluid is limited by a slow rate of induction, temperature instability, and volume overload. Endovascular catheter-based cooling may induce hypothermia more quickly (4.8±2.1°C/h), 5,6,9,12 but still not fast enough to Background-Systemic hypothermia may reduce infarct size if established before reperfusion. The large surface area of the bowel may facilitate rapid hypothermia. We therefore examined the feasibility, safety, and efficacy of hypothermia induced by an automated peritoneal lavage system in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Methods and Results-Patients with ST-segment-elevation myocardial infarction within 6 hours of symptom onset were randomized to peritoneal hypothermia before and for 3 hours after percutaneous coronary intervention versus control. The primary safety end point was the 30-day composite rate of death, reinfarction, ischemia-driven target vessel revascularization, major bleeding, sepsis, pneumonia, peritonitis, severe arrhythmia, or renal failure. The primary efficacy end point was infarct size assessed by cardiac MRI on day 3 to 5. Fifty-four patients were randomized at 7 centers to hypothermia (n=28) versus control (n=26). Hypothermia was successfully initiated in 96.3% of patients, and median [interquartile range] temperature at first balloon inflation was 34.7 [34.0-34.9]°C. Median door-to-balloon times in the hypothermia and control groups were 62 [51-81] and 47 [37-55] minutes, respectively (P=0.007). The primary safety end point occurred in 6 (21.4%) and 0 (0%) patients in the hypothermia and control groups, respectively (P=0.01), including 3 versus 0 stent thrombosis events. Infarct size was 17. 2% [15.1-20.6] and 16.1% [10.0-22.2] in the hypothermia and control groups, respectively (P=0.54). Conclusions-Peritoneal hypothermia is feasible and achieves rapid cooling with only a modest increase in treatment times in the setting of ST-segment-elevation myocardial infarction. However, in the present randomized trial, peritoneal hypothermia was associated with an increased rate of adverse events without reducing infarct size. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01655433.
Peritoneal Hypothermia in STEMI ensure adequate cooling before percutaneous coronary intervention (PCI). 13 The need exists for an even more rapid cooling method which can be regularly instituted before PCI and not excessively prolong door-to-balloon times.
Peritoneal lavage has a well-established safety profile for diagnosis of blunt abdominal injury in patients with trauma and for treatment of accidental hypothermia, end-stage renal disease, and cancer. The large surface area of the bowel may facilitate rapid hypothermia, safely reducing infarct size. A small observational study reported that peritoneal hypothermia in patients with STEMI and cardiac arrest is feasible and results in rapid cooling. 14 We therefore performed a multicenter randomized trial to assess the feasibility, safety, and efficacy of peritoneal hypothermia to reduce infarct size in patients with acute STEMI.
Methods
The Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients (VELOCITY) was performed under an Investigational Device Exemption from the Food and Drug Administration. The principal investigators designed the protocol in collaboration with the sponsor, have full access to the data, and assume responsibility for study integrity and publication of the results. The study was approved by the Institutional Review Board at each institution, and all patients provided written informed consent before enrollment.
Patient Population and Randomization
Patients were considered for enrollment who met the following inclusion criteria: age 18 to 85 years; clinical symptoms consistent with acute STEMI lasting ≥30 minutes and starting within 6 hours of hospital presentation; ≥2 mm of ST-segment-elevation in ≥2 contiguous ECG leads (or true posterior STEMI with ≥2 mm of ST-segment depression in leads V1-4 with upright T waves); and planned coronary angiography with intended primary PCI. Patients were excluded for any of the following conditions: Cardiac arrest; contraindications to peritoneal lavage, including prior intraperitoneal surgery, profound obesity, abdominal aortic aneurysm, or massive ascites; temperature-sensitive hematologic dyscrasias or vasospastic disorders (eg, Raynaud disease, Buerger's disease, cryoglobulinemia, sickle cell disease, or serum cold agglutinins); oxygen-dependent chronic obstructive pulmonary disease; pulmonary edema or cardiogenic shock; history of previous MI or pathological Q waves on a prior ECG; active uncontrolled bleeding; known hemoglobin <9 mg/dL, platelet count <100 000 or >750 000 cells/mm 3 , serum creatinine >2.0 mg/dL, dialysis or markedly abnormal liver function; contraindications for MRI, including prior pacemaker or defibrillator implant, atrial fibrillation, or claustrophobia; known allergy or intolerance to meperidine or buspirone or treatment with a monoamine oxidase inhibitor within 14 days; known hypersensitivity to contrast media or antiplatelet/antithrombotic medications which cannot be adequately premedicated; prior thrombolytic agent use for the index STEMI; chronic oral anticoagulant use; pregnant or nursing; comorbidities with life expectancy <1 year; any conditions likely leading to noncompliance with study procedures; currently enrolled in another investigational trial; or inability to provide informed consent.
Eligible, consented patients were randomly assigned using a computerized, interactive voice response system to primary PCI with peritoneal hypothermia versus primary PCI alone in a 1:1 ratio stratified by site with masked allocation in concealed blocks of 6.
Hypothermia Procedures
In the intervention group, hypothermia to ≤34.9°C was induced before PCI by lavaging the peritoneal cavity with temperature-controlled lactated Ringer's solution using the Velomedix Automated Peritoneal Lavage System (Velomedix Inc, Menlo Park, CA), consisting of a peritoneal lavage kit and controller console ( Figure 1) . The kit includes a standard commercially available blunt-tipped screw to access the peritoneal space (EndoTIP, Karl Storz, Tuttlingen, Germany), lavage catheter, core temperature probe, and catheter fixation device. Automated software manages temperature by controlling the infusion, circulation, and removal of temperature-controlled fluid in the peritoneal cavity. Hypothermia is rapidly induced before intervention and maintained for 3 hours post-PCI.
Site investigators were trained in device use using a large animal model before study participation. After insertion of the esophageal temperature probe, peritoneal access with the EndoTIP was obtained percutaneously in the midline just above the umbilical crease. The peritoneal catheter was then introduced and 2.5 to 4.5 L (depending on the peritoneal pressure) of cooled fluid was infused into the peritoneal space. After the initial fill, cold fluid was irrigated or recirculated through the peritoneal cavity until the target core temperature was reached. The controller was preprogrammed to rapidly reach ≤34.9°C, then cooled further to a target temperature of 32.5°C. Hypothermia was maintained for 3 hours after PCI, followed by active rewarming at 0.5°C/hour to 34°C over an additional 3 hours. The system automatically drains the peritoneal fluid after the warming cycle and the catheter is removed.
Shivering prophylaxis was initiated before hypothermia with buspirone 30 mg orally, meperidine 1 mg/kg intravenously over 15 to 20 minutes then 25 mg/h titrated to effect, and use of a forced-air warming blanket for skin counterwarming. Fentanyl was substituted if meperidine was ineffective, but was not used before fluid filling of the peritoneal space as it may elevate intraperitoneal pressure. 15 Intravenous magnesium and dexmedetomidine were recommended for refractory shivering.
Protocol Procedures and Medications
Both groups underwent primary PCI using standard techniques and adjunct pharmacology as per local standard of care. A 12-lead ECG was obtained at baseline and 60 minutes post-PCI and more frequently as clinically indicated. Cardiac MRI was performed at 3 to 5 days and at 30 (±7) days post-PCI as previously described. 16 Follow-up was performed at 30 days and 6 months. At the time of the present report, follow-up is complete for all patients at 30 days.
WHAT IS KNOWN
• Despite successful primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction, myocardial salvage is often suboptimal, resulting in increased rates of death and heart failure.
• Prior studies have suggested that the rapid induction of mild systemic hypothermia before intervention might reduce infarct size and improve prognosis.
WHAT THE STUDY ADDS
• Systemic hypothermia may be rapidly established with an automated peritoneal lavage system before percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction.
• A trend was present for an increased rate of stent thrombosis with hypothermia treatment, which has been suggested in some but not other retrospective studies.
• A statistically significant reduction in infarct size with hypothermia was not observed, although the outcomes tended to be better in patients with anterior compared with nonanterior myocardial infarction. Peritoneal Hypothermia in STEMI
Study End Points
The principal objectives of the study were to assess the feasibility and safety of peritoneal hypothermia in patients with STEMI undergoing primary PCI. A secondary objective was to examine whether infarct size may be reduced with this therapy. The primary safety end point was the composite rate of death, reinfarction, ischemia-driven target vessel revascularization, major bleeding, sepsis, pneumonia, peritonitis, severe arrhythmias, or renal failure occurring within 30 (±7) days after randomization. Secondary outcomes included major adverse cardiac events (MACE), defined as the composite of cardiac death, reinfarction, or ischemia-driven target vessel revascularization. Reinfarction was defined as recurrent ischemic symptoms lasting ≥30 minutes with either new ECG changes or (re)elevation of troponin or creatine phosphokinase MB isoenzyme. Stent thrombosis was defined according to the Academic Research Consortium criteria. 17 All primary and major secondary end points were adjudicated by an independent clinical events committee blinded to randomization. The primary efficacy end point was infarct size assessed by cardiac MRI on day 3 to 5, expressed as a percentage of total left ventricular (LV) mass, as assessed by an independent core laboratory blinded to randomization. The detailed methodology for infarct size assessment has been previously described. 16 Secondary MRI measures included microvascular obstruction at 3 to 5 days and LV volumes and ejection fraction at 3 to 5 and 30 days. Area at risk was evaluated using a triple inversion recovery T2-weighted turbo-spin-echo sequence with suppression pulses for blood flow (echo time 80 ms) and manually traced as the hyperintense area by visual evaluation. Device success in the hypothermia arm was defined as a decrease in core temperature to ≤34.9°C before PCI. Angiographic parameters and ST-segment resolution were evaluated in angiographic and ECG core laboratories blinded to treatment as previously described. 18, 19 
Statistical Methodology
The trial was designed to enroll a maximum of 60 patients (30 per group), a size similar to that of other randomized pilot hypothermia studies. 4, 7 No formal power analysis was performed. By intentionto-treat, patients were analyzed in their assigned group, regardless of treatment received. Efficacy analysis was performed on all randomized patients with available data. To account for patients lost to follow-up, safety event rates were estimated using Kaplan-Meier methodology and compared using the long-rank test. Categorical variables were compared using the Chi-square or Fisher exact test. Continuous variables were compared using Student's t test or Wilcoxon rank-sum test for non-normally distributed data per the Shapiro-Wilk test. Prespecified subgroup analyses included anterior versus nonanterior infarct location and symptom to hospital arrival of ≤3 versus >3 hours. Interactions between treatment and subgroup were assessed for the primary efficacy end point via a 2-way analysis of variance model. A P value <0.05 was considered statistically significant. All P values are 2-sided. No adjustments were made for multiple comparisons. All analyses were performed using SAS (version 9.2, SAS Institute, Cary, NC).
Results

Patients and Procedures
Between January 29, 2013, and January 16, 2014, 54 patients with STEMI at 7 centers in the United States and Canada were randomly allocated to treatment with primary PCI alone (n=26) or to primary PCI plus hypothermia (n=28; Figure 2 ). The baseline features of the 2 groups were well matched ( Table 1 ). The median [25th, 75th percentile] age of the patients was 57 [49, 63] years, and 46 (85.2%) were male. By ECG criteria, 25 (46.3%) of the infarcts were anterior. Medication use was also well balanced between the groups ( Table 1 ). All patients underwent emergent angiography. One patient randomized to hypothermia had an aortic dissection mimicking STEMI, which Figure 1 . The peritoneal hypothermia system. Left, The Velomedix Automated Peritoneal Lavage System includes a controller console to monitor the infusion, circulation, and removal of temperaturecontrolled fluid in the peritoneal cavity, according to the patient's core temperature as measured by an esophageal probe. Right, The peritoneal catheter is introduced in the midline above the umbilicus, through which 2.5 to 4.5 L of temperature-controlled lactated Ringer's solution is infused. The large surface area of the small intestine (which receives ≈20% of the cardiac output) serves as an effective membrane for heat exchange. 
Hypothermia and Temperature Measures
Peritoneal access was attempted in 27 patients (in the catheterization laboratory in 26 and in the emergency room in 1).
Peritoneal access was successful and hypothermia was initiated in 26 of these patients (96.3%). Administered shivering prophylaxis included buspirone, meperidine, magnesium, midazolam, fentanyl, and morphine in 28 (100%), 28 (100%), 14 (50.0%), 7 (25.0%), 2 (7.1%), and 1 (3.6%) patient(s), respectively. Forced-air warming blankets and standard blankets were also used in 25 (89.3%) and 21 
Clinical Outcomes
Follow-up at 30 days was complete in 49/54 patients; 4 control patients and 1 hypothermia patient withdrew or were lost Table 4 , the primary composite safety end point at 30 days occurred in 0 (0%) patients in the control group and 6 (21.4%) patients in the hypothermia group (P=0.01). MACE at 30 days occurred in 0 (0%) versus 4 (14.3%) patients, respectively (P=0.047). Stent thrombosis within 30 days occurred in 0 (0%) patients in the control group and in 3 (11.0%) patients in the hypothermia group (P=0.09). Ischemia-driven target vessel revascularization was performed to treat each stent thrombosis event, which drove the differences in the composite safety end point and MACE. The only death occurred postoperatively in the patient with the aortic dissection.
MRI
MRI at 3 to 5 days postprocedure (median 4 days) was completed in 46 (88.5%) of the 52 patients in whom PCI was performed. The median myocardial infarct size (%LV mass) was 16.1% [10.0, 22.2] in the control group and 17.2% [15.1, 20.6] in the hypothermia group (P=0.54). There were no significant differences in myocardial salvage, microvascular obstruction, or LV volumes or function between the groups (Table 5 ). No significant interactions were evident between treatment and infarct size according to infarct vessel or time from symptom onset to hospital arrival (Figure 3 ). Finally, infarct size and other MRI measures between the groups were not significantly different at 30 days (Table 5 ).
Discussion
In the present trial, establishment of peritoneal hypothermia before primary PCI in patients with STEMI was feasible, but did not reduce infarct size. The time required to achieve the goal temperature of ≤34.9°C prolonged door-to-balloon time modestly, and systemic hypothermia was associated with adverse events, including stent thrombosis. These findings have implications not only for the peritoneal approach to hypothermia, but also raise general questions about the utility of systemic hypothermia to reduce infarct size.
Results From Prior Studies
The present results should be interpreted in the context of prior trials that evaluated hypothermia in patients with STEMI undergoing primary PCI. In a multicenter randomized trial, 42 subjects presenting within 6 hours of STEMI onset were randomized to primary PCI with or without hypothermia to 33°C using an endovascular heat exchange catheter. 4 The mean temperature at reperfusion in the hypothermia group was 34.7±0.9°C. Door-to-balloon time was not prolonged in the hypothermia group, but reaching a goal temperature was not required before PCI. Adverse cardiac events at 30 days occurred in 10% of hypothermia patients versus 0% in the control group. Median infarct size tended to be smaller in the hypothermia group (2% versus 8% of LV mass, P=0.80). These results prompted the performance of 2 larger multicenter 5, 6 In these studies, cooling prolonged door-to-balloon times by 10 to 20 minutes. By intention-to-treat, hypothermia did not reduce infarct size in either study. Post hoc subgroup analysis in both trials suggested that patients who reached a target temperature ≤34.9°C before PCI (attained in 50% or fewer patients) had smaller infarctions compared with those that did not, especially in anterior STEMI. In both trials, MACE rates tended to be higher in the hypothermia arm.
To more rapidly induce hypothermia, Götberg et al infused 1 to 2 L of intravenous cold saline along with endovascular cooling in the hypothermia group of a 20 patient randomized trial. 7 This led to more rapid cooling, with 9/9 hypothermia patients achieving a core temperature <35°C before PCI without prolonging door-to-balloon time. Infarct size normalized to myocardium at risk was reduced in the hypothermia group (mean 30% versus 40%, P=0.04). No patient in either group experienced MACE within 30 days. This favorable experience prompted a multicenter trial of this cooling method in 120 randomized patients. 8 In the hypothermia group, 76% of patients achieved a core temperature <35°C, with door-to-balloon time prolonged by 10 minutes compared with control. There was no significant difference in infarct size normalized to area at risk (median 40.5% with hypothermia versus 46.6% with control, P=0.15). Post hoc analysis suggested that myocardial salvage was greater with hypothermia in patients with anterior infarcts who presented within 4 hours of symptom onset. MACE was not increased with hypothermia, and heart failure was reduced at 45 days in the hypothermia group (3% versus 14% with control, P=0.047).
Results of the Current Study: Infarct Size
In the VELOCITY trial, peritoneal hypothermia was feasible in 96.3% of patients with STEMI and achieved the goal temperature of ≤34.9°C before PCI in 88.9% of patients at median 17 minutes. However, hypothermia did not reduce infarct size. It is possible that the prolonged door-to-balloon time in the hypothermia group may have attenuated the effect of hypothermia on infarct size. Observational studies have demonstrated an important relationship between reperfusion delays and mortality in STEMI. 20, 21 However, door-to-balloon times were short in both groups and within the range wherein further reductions in mortally may not be realized. 13 It is thus unlikely that the 15 minute delay to reperfusion in the hypothermia arm is totally responsible for the absence of effect. Furthermore, in contrast to prior studies, no significant interactions were present between infarct location and presentation time, although the results with hypothermia were slightly more favorable in patients with anterior compared with nonanterior infarction. Nonetheless, any delays in treatment times are undesirable, especially in patients presenting early after infarct onset. Finally, the modest size of the present trial may have precluded demonstrating a reduction in infarct size with hypothermia. Hypothermia has consistently been shown to reduce infarct size in experimental models, especially when established before reperfusion. 2,3,22-25 A large-scale, appropriately powered trial is clearly needed to determine whether the rapid induction of mild systemic hypothermia reduces infarct size and improves clinical outcomes in patients with STEMI undergoing primary PCI.
Results of the Current Study: Safety
In the present study, hypothermia was associated with a trend toward an increased rate of stent thrombosis. Given chronic use of dual antiplatelet therapy, <80% of patients received aspirin or ADP antagonists before PCI, which may have contributed to the thrombosis risk in the hypothermia group (although no control patients developed stent thrombosis). Prior prospective studies investigating hypothermia during primary PCI have not reported stent thrombosis rates. Hypothermia increases platelet activation, which directly contributes to thrombosis 26 and, in addition, may attenuate the efficacy of ADP antagonists. 27, 28 Hypothermia may also induce cholesterol crystallization, which could trigger plaque rupture. 29 It is also possible that hypothermia may delay gastric absorption and reduce the bioavailability of oral antiplatelet agents. 30 Penela et al described that among 16 patients presenting with acute coronary syndromes and cardiac arrest treated with PCI and hypothermia, 5 (31.2%) developed stent thrombosis within 30 days. 31 Conversely, in a consecutive series of 1334 patients with STEMI undergoing PCI, hypothermia in 75 cardiac arrest patients was not associated with an increased rate of stent thrombosis compared with control. 32 Future trials should carefully examine the risk of stent thrombosis with hypothermia, although large prospective studies may be required to determine whether hypothermia is causally related to this event. Peritoneal hypothermia may have other safety concerns. Respiratory suppression may occur because of decreased diaphragm excursion coupled with use of sedation and narcotics for shivering suppression. Several such cases occurred early in the trial, which were subsequently averted by recommending lower meperidine doses, earlier use of magnesium or dexmedetomidine, and careful monitoring of respiratory status. Major organ bleeding is a concern after peritoneal puncture, especially given the use of potent antithrombotic and antiplatelet agents in STEMI. Such complications can be circumvented through careful patient selection (avoiding those with prior abdominal procedures or pathology) and with careful technique. In the present study, no patient developed major bleeding or organ damage related to the peritoneal access procedure.
Limitations
First, the nature of the intervention necessitated unblinding the operators after randomization. However, potential bias was mitigated by blinded adjudication of clinical events and assessment of diagnostic results by core laboratories masked to treatment allocation. Second, patients with both anterior and nonanterior infarcts were enrolled, and the study was not powered to demonstrate a reduction in infarct size. The results may have been improved if only anterior infarcts were included, which by nature have more myocardium at risk and may biologically respond differently than nonanterior infarcts. Similarly, the study lacked power to detect differences in clinical outcomes. Third, the optimal goal temperature before reperfusion and duration of hypothermia in humans is not known; the metrics selected for the present trial are consistent with those from prior studies, but may not be ideal. Fourth, the sponsor terminated enrolment before the maximum 60 patients were randomized because of slow recruitment (not because of safety concerns). In hindsight, enrolling 6 more patients would most likely have not changed the safety or efficacy findings. Finally, long-term follow-up is not available.
Conclusions
Controlled systemic hypothermia through automated peritoneal lavage may be safely and rapidly established in patients with evolving STEMI undergoing primary PCI at the expense of a modest increase in door-to-balloon time. In the present randomized trial, peritoneal hypothermia was associated with an increased rate of adverse events (including stent thrombosis) without reducing infarct size. Adequately powered randomized trials (likely limited to patients with anterior MI) are needed to assess the effect of rapidly induced hypothermia on myocardial salvage and clinical outcomes after primary PCI.
